Investigational drug · Phase 3
Suvemcitug
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Refractory Metastatic Colorectal Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "Suvemcitug"
First trial start
2025
Nov 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Suvemcitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Refractory Metastatic Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Suvemcitug" as an intervention, largest first.
- A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal CancerPivotal-lookingRecruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT07361003 · 464 participants (planned) · Start Nov 12, 2025 · Primary completion Jan 2028
Drug: Suvemcitug injection, trifluridine/tipiracil tablets; Suvemcitug placebo injection, trifluridine/tipiracil tablets · For: Refractory Metastatic Colorectal Cancer
Sites: Fuzhou, China; Harbin, China; Nanjing, China · 6 sites in all
- MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian CancerNot yet recruiting
Tongji HospitalAcademic, hospital or other
NCT07934121 · 80 participants (planned) · Start Nov 10, 2026 · Primary completion Jun 30, 2028
Drug: Mirvetuximab Soravtansine; Suvemcitug · For: Platinum-Sensitive Recurrent Ovarian Cancer
Sites: Wuhan, China
- Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian CancerNot yet recruiting
Anhui Provincial HospitalGovernment (non-federal)
NCT07920159 · 76 participants (planned) · Start Jan 1, 2027 · Primary completion Sep 30, 2028
Drug: Suvemcitug · For: High-grade Serous Ovarian Cancer
- Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal CancerNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07810114 · 52 participants (planned) · Start Aug 28, 2026 · Primary completion Dec 1, 2027
Drug: mFOLFOX6; Suvemcitug and 1 more · For: Rectal Cancer
Sites: Shanghai, China
- Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC ConversionNot yet recruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT07738055 · 35 participants (planned) · Start Jul 31, 2026 · Primary completion Jan 31, 2029
Drug: Envafolimab: 400mg, subcutaneous injection Suvemcitug: 2mg/kg, intravenous injection HAIC: Oxaliplatin 85mg/m² + 5-FU 2400-3200mg/m², continuous infusion, every 3 weeks · For: Potentially Resectable Hepatocellular Carcinoma
- Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerNot yet recruiting
Peking University Third HospitalAcademic, hospital or other
NCT07741630 · 20 participants (planned) · Start Aug 15, 2026 · Primary completion Jun 30, 2027
Drug: Mirvetuximab soravtansine; Suvemcitug · For: PROC
- Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical TrialNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07774754 · 18 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 1, 2028
Drug: Drug:sintilimab; Drug:Capecitabine and 1 more · For: Rectal Cancer
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.
Yuan G, Lou G, Li J, et al. · Nat Cancer 2026
- Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.
Ma L, Zhang Y, Fang Y, et al. · Invest New Drugs 2025
- The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study.
Liu Y, Wang J, Fang Y, et al. · Int J Colorectal Dis 2025
- Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
Yuan G, Zhang K, Zheng H, et al. · Gynecol Oncol 2024
- Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.
Mao C, Ji D, Ding Y, et al. · ESMO Open 2023
Also in development for Refractory Metastatic Colorectal Cancer
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- CR6086vorbipiprantPhase 21 trial
Rottapharm Biotech · Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.